×
About 358 results

ALLMedicine™ Generalized Lipodystrophy Center

Research & Reviews  130 results

Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy
https://clinicaltrials.gov/ct2/show/NCT02262832

Jun 24th, 2022 - Leptin is an adipocyte-derived hormone that can be thought of as a signal from adipose tissue to the rest of the body conveying information about long-term nutritional status. Patients with the very rare condition of generalized lipodystrophy have...

Autoantibodies to Perilipin-1 Define a Subset of Acquired Generalized Lipodystrophy.
https://doi.org/10.2337/db21-1172
Diabetes Mandel-Brehm C, Vazquez SE et. al.

Jun 17th, 2022 - Acquired lipodystrophy is often characterized as an idiopathic subtype of lipodystrophy. Despite suspicion of an immune-mediated pathology, biomarkers such as autoantibodies are generally lacking. Here, we used an unbiased proteome-wide screening ...

Dermatologic Manifestations of Generalized Lipodystrophy Treatment & Management
https://emedicine.medscape.com/article/1113171-treatment

Jun 17th, 2022 - Medical Care Successful treatment of acanthosis nigricans (AN) in association with generalized lipodystrophy was accomplished in 1 patient with etretinate beginning at 75 mg/d. [21] Therapy for AN was undertaken in this patient for cosmetic reason...

Dermatologic Manifestations of Generalized Lipodystrophy
https://emedicine.medscape.com/article/1113171-overview

Jun 17th, 2022 - Practice Essentials Generalized lipodystrophy syndrome is the association of acanthosis nigricans (AN) with the generalized complete absence of subcutaneous fat and the presence of muscle hypertrophy, hyperlipemia, diabetes mellitus, and hepatospl...

Dermatologic Manifestations of Generalized Lipodystrophy
https://emedicine.medscape.com/article/1113171-print

Jun 17th, 2022 - Practice Essentials Generalized lipodystrophy syndrome is the association of acanthosis nigricans (AN) with the generalized complete absence of subcutaneous fat and the presence of muscle hypertrophy, hyperlipemia, diabetes mellitus, and hepatospl...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  4 results

Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy
https://clinicaltrials.gov/ct2/show/NCT02262832

Jun 24th, 2022 - Leptin is an adipocyte-derived hormone that can be thought of as a signal from adipose tissue to the rest of the body conveying information about long-term nutritional status. Patients with the very rare condition of generalized lipodystrophy have...

Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy
https://clinicaltrials.gov/ct2/show/NCT04159415

Mar 10th, 2022 - The primary objectives of the study are to estimate the effects of REGN4461 on glycemic parameters in the subset of patients with elevated baseline hemoglobin A1c levels (HbA1c ≥7%) and to estimate the effects of REGN4461 on fasting triglyceride l...

The Effects of Metreleptin in Congenital Leptin Deficiency
https://clinicaltrials.gov/ct2/show/NCT04063488

Dec 30th, 2021 - Congenital leptin deficiency (CLD) is a rare autosomal recessive condition caused by a mutation in the leptin gene (LEP). This mutation leads to a severe deficiency in leptin, a hormone secreted primarily by adipocytes. Leptin is also secreted by ...

Immunogenicity of Metreleptin in Patients With Generalized Lipodystrophy
https://clinicaltrials.gov/ct2/show/NCT04026178

Jul 9th, 2020 - MYALEPT™ (metreleptin) has been approved as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy (MYALEPT Prescribing Information). This study i...

see more →

News  8 results

EMA Panel Recommends Metreleptin for Leptin Deficiency
https://www.medscape.com/viewarticle/897471

Jun 1st, 2018 - The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended marketing authorization for metreleptin (Myalepta, Aegerion Pharmaceuticals BV) for the treatment of complicaitons of leptin deficiency in those with...

Table of Surrogate Endpoints That Were the Basis of Drug Approval or Licensure
http://www.fda.gov/drugs/development-resources/table-surrogate-endpoints-were-basis-drug-approval-or-licensure

What is the purpose of the Surrogate Endpoint Table? FDA’s surrogate endpoint table provides valuable information for drug developers on endpoints that may be considered and discussed with FDA for individual development programs. This table also f...

FDA OKs Myalept for Leptin Deficiency
https://www.medpagetoday.com/endocrinology/generalendocrinology/44477

Feb 25th, 2014 - The FDA has approved metreleptin (Myalept) for congenital or acquired generalized lipodystrophy, the agency announced. The leptin analog injection will be used alongside diet to relieve the symptoms of this condition, in which patients are born wi...

Myalept (Metreleptin) Approved for Generalized Lipodystrophy
https://www.staging.medscape.com/viewarticle/821056

Feb 25th, 2014 - The US Food and Drug Administration (FDA) has approved Amylin Pharmaceuticals' Myalept (metreleptin for injection) as replacement therapy to treat the complications of leptin deficiency, in addition to diet, in patients with congenital generalized...

Myalept (Metreleptin) Approved for Generalized Lipodystrophy
https://www.medscape.com/viewarticle/821056

Feb 25th, 2014 - The US Food and Drug Administration (FDA) has approved Amylin Pharmaceuticals' Myalept (metreleptin for injection) as replacement therapy to treat the complications of leptin deficiency, in addition to diet, in patients with congenital generalized...

see more →